Susquehanna International Group’s Structure Therapeutics GPCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.66M Sell
117,500
-6,200
-5% -$424K ﹤0.01% 4019
2025
Q4
$8.6M Sell
123,700
-121,300
-50% -$4.95M ﹤0.01% 3255
2025
Q3
$6.86M Buy
245,000
+138,900
+131% +$2.77M ﹤0.01% 3592
2025
Q2
$2.2M Sell
106,100
-31,500
-23% -$693K ﹤0.01% 5596
2025
Q1
$2.38M Buy
137,600
+19,200
+16% +$470K ﹤0.01% 5147
2024
Q4
$3.21M Buy
118,400
+17,300
+17% +$614K ﹤0.01% 4358
2024
Q3
$4.44M Sell
101,100
-70,600
-41% -$2.73M ﹤0.01% 3792
2024
Q2
$6.74M Buy
171,700
+23,600
+16% +$969K ﹤0.01% 2986
2024
Q1
$6.35M Buy
148,100
+59,000
+66% +$2.49M ﹤0.01% 3249
2023
Q4
$3.63M Buy
+89,100
New +$5.11M ﹤0.01% 4265

Other funds holding GPCR

Susquehanna International Group's GPCR Position: Q1 2026 in Review

Susquehanna International Group increased its Structure Therapeutics (GPCR) stake by 521% in Q1 2026, buying an estimated $3.21M and bringing the position to 55,842 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #5501.

Susquehanna International Group first reported a position in GPCR in Q4 2023 and has held it in 10 quarters since. The position peaked at $5.98M in Q3 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Susquehanna International Group held 55,842 shares of Structure Therapeutics worth $2.69M as of Q1 2026.
  • Susquehanna International Group bought 46,843 Structure Therapeutics shares in Q1 2026, an estimated $3.21M.
  • Structure Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5501 holding.
  • Susquehanna International Group first reported a position in Structure Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Susquehanna International Group's Structure Therapeutics position peaked at $5.98M in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.